Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer

Kunimitsu Kanai, Jun Nakashima, Akitomo Sugawara, Naoyuki Shigematsu, Hirohiko Nagata, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Atsushi Kubo, Mototsugu Oya

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: We aimed to calculate the frequency and features of the development of a prostate-specific antigen (PSA) bounce after prostate brachytherapy alone, to correlate the bounce with clinical and dosimetric factors and to identify factors that predict PSA bounce. Methods: PSA bounce was evaluated in 86 patients with T1-T2 prostate cancer who underwent radioactive seed implantation using iodine-125 (I-125) without hormonal therapy or external-beam radiation therapy (EBRT) from September 2004 to December 2007. A PSA bounce was defined as a rise of at least 0.4 ng/ml greater than a previous PSA level with a subsequent decline equal to, or less than, the initial nadir. Results: Calculated by the Kaplan-Meier method, the incidence of PSA bounce at a 2-year follow-up was 26%. Median time to the PSA bounce was 15 months. Univariate analysis demonstrated that age, dose received by 90% of the prostate gland (D90), volume of gland receiving 100% of the prescribed dose (V100), and V150 were significantly associated with the PSA bounce, while pretreatment PSA level, Gleason score, pretreatment prostate volume, clinical T stage, and V200 were not. In multivariate analysis, age 67 years or less and D90 more than 180 Gy were identified as independent factors for predicting the PSA bounce (P < 0.05). Conclusion: PSA bounce is not a rare phenomenon after prostate brachytherapy. It is more common in younger patients and patients receiving higher doses of radiation.

Original languageEnglish
Pages (from-to)502-506
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume14
Issue number6
DOIs
Publication statusPublished - 2009 Dec

Fingerprint

Brachytherapy
Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Neoplasm Grading
Iodine
Seeds
Radiotherapy
Multivariate Analysis
Radiation

Keywords

  • Brachytherapy
  • Prostate cancer
  • PSA bounce

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. / Kanai, Kunimitsu; Nakashima, Jun; Sugawara, Akitomo; Shigematsu, Naoyuki; Nagata, Hirohiko; Kikuchi, Eiji; Miyajima, Akira; Nakagawa, Ken; Kubo, Atsushi; Oya, Mototsugu.

In: International Journal of Clinical Oncology, Vol. 14, No. 6, 12.2009, p. 502-506.

Research output: Contribution to journalArticle

Kanai, K, Nakashima, J, Sugawara, A, Shigematsu, N, Nagata, H, Kikuchi, E, Miyajima, A, Nakagawa, K, Kubo, A & Oya, M 2009, 'Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer', International Journal of Clinical Oncology, vol. 14, no. 6, pp. 502-506. https://doi.org/10.1007/s10147-009-0909-0
Kanai, Kunimitsu ; Nakashima, Jun ; Sugawara, Akitomo ; Shigematsu, Naoyuki ; Nagata, Hirohiko ; Kikuchi, Eiji ; Miyajima, Akira ; Nakagawa, Ken ; Kubo, Atsushi ; Oya, Mototsugu. / Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. In: International Journal of Clinical Oncology. 2009 ; Vol. 14, No. 6. pp. 502-506.
@article{8664fa68c21542b1ab7b6b9b3ed3cfdb,
title = "Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer",
abstract = "Background: We aimed to calculate the frequency and features of the development of a prostate-specific antigen (PSA) bounce after prostate brachytherapy alone, to correlate the bounce with clinical and dosimetric factors and to identify factors that predict PSA bounce. Methods: PSA bounce was evaluated in 86 patients with T1-T2 prostate cancer who underwent radioactive seed implantation using iodine-125 (I-125) without hormonal therapy or external-beam radiation therapy (EBRT) from September 2004 to December 2007. A PSA bounce was defined as a rise of at least 0.4 ng/ml greater than a previous PSA level with a subsequent decline equal to, or less than, the initial nadir. Results: Calculated by the Kaplan-Meier method, the incidence of PSA bounce at a 2-year follow-up was 26{\%}. Median time to the PSA bounce was 15 months. Univariate analysis demonstrated that age, dose received by 90{\%} of the prostate gland (D90), volume of gland receiving 100{\%} of the prescribed dose (V100), and V150 were significantly associated with the PSA bounce, while pretreatment PSA level, Gleason score, pretreatment prostate volume, clinical T stage, and V200 were not. In multivariate analysis, age 67 years or less and D90 more than 180 Gy were identified as independent factors for predicting the PSA bounce (P < 0.05). Conclusion: PSA bounce is not a rare phenomenon after prostate brachytherapy. It is more common in younger patients and patients receiving higher doses of radiation.",
keywords = "Brachytherapy, Prostate cancer, PSA bounce",
author = "Kunimitsu Kanai and Jun Nakashima and Akitomo Sugawara and Naoyuki Shigematsu and Hirohiko Nagata and Eiji Kikuchi and Akira Miyajima and Ken Nakagawa and Atsushi Kubo and Mototsugu Oya",
year = "2009",
month = "12",
doi = "10.1007/s10147-009-0909-0",
language = "English",
volume = "14",
pages = "502--506",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer

AU - Kanai, Kunimitsu

AU - Nakashima, Jun

AU - Sugawara, Akitomo

AU - Shigematsu, Naoyuki

AU - Nagata, Hirohiko

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Kubo, Atsushi

AU - Oya, Mototsugu

PY - 2009/12

Y1 - 2009/12

N2 - Background: We aimed to calculate the frequency and features of the development of a prostate-specific antigen (PSA) bounce after prostate brachytherapy alone, to correlate the bounce with clinical and dosimetric factors and to identify factors that predict PSA bounce. Methods: PSA bounce was evaluated in 86 patients with T1-T2 prostate cancer who underwent radioactive seed implantation using iodine-125 (I-125) without hormonal therapy or external-beam radiation therapy (EBRT) from September 2004 to December 2007. A PSA bounce was defined as a rise of at least 0.4 ng/ml greater than a previous PSA level with a subsequent decline equal to, or less than, the initial nadir. Results: Calculated by the Kaplan-Meier method, the incidence of PSA bounce at a 2-year follow-up was 26%. Median time to the PSA bounce was 15 months. Univariate analysis demonstrated that age, dose received by 90% of the prostate gland (D90), volume of gland receiving 100% of the prescribed dose (V100), and V150 were significantly associated with the PSA bounce, while pretreatment PSA level, Gleason score, pretreatment prostate volume, clinical T stage, and V200 were not. In multivariate analysis, age 67 years or less and D90 more than 180 Gy were identified as independent factors for predicting the PSA bounce (P < 0.05). Conclusion: PSA bounce is not a rare phenomenon after prostate brachytherapy. It is more common in younger patients and patients receiving higher doses of radiation.

AB - Background: We aimed to calculate the frequency and features of the development of a prostate-specific antigen (PSA) bounce after prostate brachytherapy alone, to correlate the bounce with clinical and dosimetric factors and to identify factors that predict PSA bounce. Methods: PSA bounce was evaluated in 86 patients with T1-T2 prostate cancer who underwent radioactive seed implantation using iodine-125 (I-125) without hormonal therapy or external-beam radiation therapy (EBRT) from September 2004 to December 2007. A PSA bounce was defined as a rise of at least 0.4 ng/ml greater than a previous PSA level with a subsequent decline equal to, or less than, the initial nadir. Results: Calculated by the Kaplan-Meier method, the incidence of PSA bounce at a 2-year follow-up was 26%. Median time to the PSA bounce was 15 months. Univariate analysis demonstrated that age, dose received by 90% of the prostate gland (D90), volume of gland receiving 100% of the prescribed dose (V100), and V150 were significantly associated with the PSA bounce, while pretreatment PSA level, Gleason score, pretreatment prostate volume, clinical T stage, and V200 were not. In multivariate analysis, age 67 years or less and D90 more than 180 Gy were identified as independent factors for predicting the PSA bounce (P < 0.05). Conclusion: PSA bounce is not a rare phenomenon after prostate brachytherapy. It is more common in younger patients and patients receiving higher doses of radiation.

KW - Brachytherapy

KW - Prostate cancer

KW - PSA bounce

UR - http://www.scopus.com/inward/record.url?scp=72949105857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949105857&partnerID=8YFLogxK

U2 - 10.1007/s10147-009-0909-0

DO - 10.1007/s10147-009-0909-0

M3 - Article

C2 - 19967485

AN - SCOPUS:72949105857

VL - 14

SP - 502

EP - 506

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 6

ER -